Capitalizing on more than 35 years of TG2 research and drug development expertise

Claire O’Brien is Vice President of Research & Development Project Management at Cambrian Bio. She has 30 years of experience in developing medicines at Ipsen, GlaxoSmithKline (including Glaxo Wellcome and Glaxo Group Research), and in biotech, an in-depth knowledge of medicine development, and a track record in leading global, matrixed teams to advance programs through discovery, development, and launch. After earning a degree in chemistry at Kingston University London, she spent ten years in formulation and analytical development, then moved into cross-functional project leadership, working in multiple disease areas and with teams across US, EU, China, and Japan. Her deep interest in the development and growth of talent has been a theme throughout her career, and she has been coaching for 15 years with a particular interest in coaching scientists to lead.

Wenjie Luo serves as Director of Business Operations at Cambrian Bio. Prior to joining Cambrian, she was the Senior Business Development Associate at Cresilon, a biotechnology startup, where she led numerous initiatives to better the company's business development and operations, including securing a $3M non-dilutive capital grant to expand the company's regional footprint. She has also served as a researcher at academic laboratories at Columbia and Cornell Universities. Luo earned her Master of Science in Biomedical Engineering from Columbia University and Bachelor of Science in Biological Engineering from Cornell University.

Andrew is a medical chemist with over 30 years’ drug discovery experience across large pharma and biotechnology. He joined Domainex as a group leader in November 2019 before attaining director of medicinal chemistry in 2022. Prior to joining the Domainex team Andrew had worked at Rhone Poulenc Rorer, Celltech, UCB, Cellzome, Redx Anti-infectives and Novintum Bioscience. During this time he has strongly contributed and taken a leadership role in delivering research projects from hit identification to candidate nomination, cumulating in the nomination of multiple small molecule candidates in the areas of MS (2 VLA4 integrin antagonists), RA (2 JAK kinase inhibitors) and Oncology (Mitochondrial disruptor). CDP323 (VLA4 integrin antagonist) progressed to phase II trials in MS. Other key areas of research have focused on PDEIV inhibitors, IMPDH inhibitors, JNK and PI3Kdelta kinase inhibitors [which ultimately led to identification and progression of UCB5857 into clinical trials], and DNA Gyrase inhibitors as anti-bacterials [which led to European funding through the ENABLE initiative]. Andrew has also experience in IP management and played a proactive committee role as vice chair & chairman of the Society of Medicines, a multi-disciplinary society engaged in promoting drug research.